Published in Eur J Clin Pharmacol on May 01, 2007
Cracking the BAFF code. Nat Rev Immunol (2009) 3.95
Clinical targeting of the TNF and TNFR superfamilies. Nat Rev Drug Discov (2013) 1.53
Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics. Crit Rev Biotechnol (2013) 1.31
Atacicept in relapsed/refractory multiple myeloma or active Waldenström's macroglobulinemia: a phase I study. Br J Cancer (2009) 1.17
Atacicept: targeting B cells in multiple sclerosis. Ther Adv Neurol Disord (2010) 1.08
A perspective on B-cell-targeting therapy for SLE. Mod Rheumatol (2009) 1.03
A mathematical analysis of rebound in a target-mediated drug disposition model: I.without feedback. J Math Biol (2013) 0.84
Manipulating B cell homeostasis: a key component in the advancement of targeted strategies. Arch Immunol Ther Exp (Warsz) (2008) 0.80
Profile of atacicept and its potential in the treatment of systemic lupus erythematosus. Drug Des Devel Ther (2015) 0.80
B-cell survival factors in autoimmune rheumatic disorders. Ther Adv Musculoskelet Dis (2015) 0.78
TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature (2000) 6.54
BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med (1999) 6.27
BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science (1999) 5.99
Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjögren's syndrome. J Clin Invest (2002) 4.14
Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus. J Immunol (2001) 3.87
Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum (2001) 3.72
TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease. impaired B cell maturation in mice lacking BLyS. Immunity (2001) 3.43
APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth. J Exp Med (1998) 3.17
Local production of B lymphocyte stimulator protein and APRIL in arthritic joints of patients with inflammatory arthritis. Arthritis Rheum (2003) 2.21
BAFF, APRIL and their receptors: structure, function and signaling. Semin Immunol (2006) 2.09
Identification of proteoglycans as the APRIL-specific binding partners. J Exp Med (2005) 2.03
An APRIL to remember: novel TNF ligands as therapeutic targets. Nat Rev Drug Discov (2006) 1.84
The role of the BAFF/APRIL system on T cell function. Semin Immunol (2006) 1.62
Heparan sulfate proteoglycan binding promotes APRIL-induced tumor cell proliferation. Cell Death Differ (2005) 1.46
A BAFF antagonist suppresses experimental autoimmune encephalomyelitis by targeting cell-mediated and humoral immune responses. Int Immunol (2006) 0.95
Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood (2013) 1.84
A randomised phase I study of etrolizumab (rhuMAb β7) in moderate to severe ulcerative colitis. Gut (2012) 1.73
A novel PEGylated interferon beta-1a for multiple sclerosis: safety, pharmacology, and biology. J Clin Pharmacol (2011) 1.33
Protein therapeutics: new applications for pharmacogenetics. Nat Rev Drug Discov (2006) 1.15
Population pharmacokinetic and pharmacodynamic modeling of etanercept using logistic regression analysis. Clin Pharmacol Ther (2003) 1.15
Use of quantitative pharmacology in the development of HAE1, a high-affinity anti-IgE monoclonal antibody. AAPS J (2008) 1.09
Population pharmacokinetic analysis and simulation of the time-concentration profile of etanercept in pediatric patients with juvenile rheumatoid arthritis. J Clin Pharmacol (2005) 1.07
PEGylated interferon beta-1a: meeting an unmet medical need in the treatment of relapsing multiple sclerosis. J Interferon Cytokine Res (2010) 1.03
A randomized, double-blind, placebo-controlled study to investigate the safety, tolerability, and pharmacokinetics of single enantiomer (+)-mefloquine compared with racemic mefloquine in healthy persons. Am J Trop Med Hyg (2010) 0.99
Population pharmacokinetics of rituximab in patients with chronic lymphocytic leukemia. J Clin Pharmacol (2012) 0.96
In vivo pharmacology and toxicology evaluation of polyethylene glycol-conjugated interferon beta-1a. J Pharmacol Exp Ther (2011) 0.92
Nonclinical safety, pharmacokinetics, and pharmacodynamics of atacicept. Toxicol Sci (2008) 0.91
The pharmacokinetics of etanercept in patients with end-stage renal disease on haemodialysis. J Pharm Pharmacol (2005) 0.91
Exposure-response analysis of pertuzumab in HER2-positive metastatic breast cancer: absence of effect on QTc prolongation and other ECG parameters. Cancer Chemother Pharmacol (2013) 0.90
Pharmacokinetics of recombinant human growth hormone administered by cool.click 2, a new needle-free device, compared with subcutaneous administration using a conventional syringe and needle. BMC Clin Pharmacol (2007) 0.89
An investigation of the safety and pharmacokinetics of the novel TRPV1 antagonist XEN-D0501 in healthy subjects. Br J Clin Pharmacol (2011) 0.89
Pharmacokinetics and biological activity of atacicept in patients with rheumatoid arthritis. J Clin Pharmacol (2008) 0.88
Targeting immune complex-mediated hypersensitivity with recombinant soluble human FcgammaRIA (CD64A). J Immunol (2008) 0.87
Nonclinical development of a biosimilar: the current landscape. Bioanalysis (2013) 0.87
Storm forecasting: additional lessons from the CD28 superagonist TGN1412 trial. Nat Rev Immunol (2012) 0.87
Preclinical safety of recombinant human thrombin. Regul Toxicol Pharmacol (2006) 0.86
Characterization of the long-term pharmacokinetics of bevacizumab following last dose in patients with resected stage II and III carcinoma of the colon. Cancer Chemother Pharmacol (2012) 0.86
Population pharmacokinetic and covariate analysis of pertuzumab, a HER2-targeted monoclonal antibody, and evaluation of a fixed, non-weight-based dose in patients with a variety of solid tumors. Cancer Chemother Pharmacol (2014) 0.86
Pharmacokinetics and pharmacodynamics of peginterferon beta-1a in patients with relapsing-remitting multiple sclerosis in the randomized ADVANCE study. Br J Clin Pharmacol (2015) 0.85
Absolute oral bioavailability of almorexant, a dual orexin receptor antagonist, in healthy human subjects. Pharmacology (2012) 0.83
Pharmacokinetics, pharmacodynamics, and safety of peginterferon beta-1a in subjects with normal or impaired renal function. J Clin Pharmacol (2014) 0.83
Phase I clinical study of atacicept in patients with relapsed and refractory B-cell non-Hodgkin's lymphoma. Clin Cancer Res (2008) 0.82
Absence of pharmacokinetic drug-drug interaction of pertuzumab with trastuzumab and docetaxel. Anticancer Drugs (2013) 0.81
Population pharmacokinetic modelling of recombinant factor IX Fc fusion protein (rFIXFc) in patients with haemophilia B. Clin Pharmacokinet (2014) 0.80
Tolerability and pharmacokinetics of delayed-release dimethyl fumarate administered with and without aspirin in healthy volunteers. Clin Ther (2013) 0.79
Modeling the exposure-response relationship of etanercept in the treatment of patients with chronic moderate to severe plaque psoriasis. J Clin Pharmacol (2007) 0.78
Physiologically based pharmacokinetic modeling of drug disposition in rat and human: a fuzzy arithmetic approach. Pharm Res (2008) 0.77
Fuzzy least squares for identification of individual pharmacokinetic parameters. IEEE Trans Biomed Eng (2009) 0.77
Pharmacokinetics of renally excreted drug dexpramipexole in subjects with impaired renal function. J Clin Pharmacol (2014) 0.75
Population-based efficacy modeling of omalizumab in patients with severe allergic asthma inadequately controlled with standard therapy. AAPS J (2013) 0.75
Pharmacokinetics and pharmacodynamics of anti-BR3 monoclonal antibody in mice. Pharm Res (2012) 0.75
Reply: To PMID 19798640. Ann Neurol (2010) 0.75
Highlights from a recent BIO survey on therapeutic protein-drug interactions. J Clin Pharmacol (2011) 0.75
Clinical pharmacokinetics of tonapofylline: evaluation of dose proportionality, oral bioavailability, and gender and food effects in healthy human subjects. J Clin Pharmacol (2010) 0.75
Simulating pharmacokinetic and pharmacodynamic fuzzy-parameterized models: a comparison of numerical methods. J Pharmacokinet Pharmacodyn (2007) 0.75
Safety and systemic absorption of pulmonary delivered human IFN-beta1a in the nonhuman primate: comparison with subcutaneous dosing. J Interferon Cytokine Res (2002) 0.75